The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Open accessAbstract
Purpose: Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC. Patients and Methods: This was a multi-institutional phase II study of selumetinib at 100 mg given orally twice per day to patients with advanced BC. The primary end point was response rate. All patients were required to provide tissue before enrolling. The levels of phosphorylated ERK (pERK) and AKT (pAKT) were assessed by immunohistochemistry. Tumors were genotyped for the presence of BRAF- and/or RAS-activating mutations. Results: Twenty-eight eligible patients with a median age of 55.6 years were enrolled. Thirty-nine percent of patients had received one prior systemic therapy. Three patients (12%) had a confirmed objective response. Another 17 patients (68%) experienced stable disease (SD), 14 of whom (56%) experienced prolonged SD (> 16 weeks). Patients gained an average nonfluid weight of 8.6 pounds. Median progression-free survival was 3.7 months (95% CI, 3.5 to 4.9) and median overall survival was 9.8 months (95% CI, 5.97 to not available). Toxicities were mild, with rash (90%) and xerostomia (54%) being most frequent. Only one patient experienced grade 4 toxicity (fatigue). All patients had tissue available for analysis. No BRAF V600E mutations were found. Two patients with short-lived SD had KRAS mutations. Absence of pERK staining was associated with lack of response. Conclusion: Selumetinib displays interesting activity and acceptable tolerability in patients with metastatic BC. Our results warrant further evaluation of selumetinib in patients with metastatic BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109
Self-citationRetractedNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Self-citationPhosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
Eckel, F., & Schmid, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603648 · Cited by 464
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Self-citationMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 318
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Self-citationThe role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 234
Wehbe, H., Henson, R., Meng, F., Mize-Berge, J., & Patel, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2130 · Cited by 224
The role of cytokines in cancer cachexia
Argilés, J. M., Busquets, S., Toledo, M., & López-Soriano, F. J. (2009) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0b013e3283311d09 · Cited by 211
Marks, J. L., Gong, Y., Chitale, D., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 211
Banerji, U., Camidge, D. R., Verheul, H. M. W., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M. E., Timmer-Bonte, J. N. H., Eckhardt, S. G., Lewis, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2483 · Cited by 211
Systemic Therapy for Biliary Tract Cancers
Hezel, A. F., & Zhu, A. X. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0252 · Cited by 208
Park, J., Tadlock, L., Gores, G. J., & Patel, T. (1999) · Hepatology · doi:10.1002/hep.510300522 · Cited by 206
Conferring specificity on the ubiquitous Raf/MEK signalling pathway
O'Neill, E., & Kolch, W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601488 · Cited by 162
Bennouna, J., Láng, I., Valladares‐Ayerbes, M., Boér, K., Adenis, A., Escudero, P., Kim, T. Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 141
Dummer, R., Robert, C., Chapman, P. B., Sosman, J. A., Middleton, M. R., Bastholt, L., Kemsley, K., Cantarini, M., Morris, C., & Kirkwood, J. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9033 · Cited by 132
Meng, F., Yamagiwa, Y., Ueno, Y., & Patel, T. C. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.030 · Cited by 128
Targeting BRAF in thyroid cancer
Espinosa, A. V., Porchia, L. M., & Ringel, M. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603520 · Cited by 104
Self-citationAssociation of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer
Zhang, D., Zheng, H., Zhou, Y., Tang, X., Baojun, Y., & Li, J. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-45 · Cited by 81
Saetta, A. A., Papanastasiou, P., Michalopoulos, N., Gigelou, F., Korkolopoulou, P. A., Bei, T., & Patsouris, E. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1046-9 · Cited by 71
Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion
Leelawat, K., Leelawat, S., Narong, S., & Hongeng, S. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i10.1561 · Cited by 70
Wickenden, J. A., Jin, H., Johnson, M., Gillings, A. S., Newson, C., Austin, M. J., Chell, S. D., Balmanno, K., Pritchard, C. A., & Cook, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.335 · Cited by 69
Pharmacologic Inhibitors of MKK1 and MKK2
Ahn, N. G., Nahreini, T. S., Tolwinski, N. S., & Resing, K. A. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)32219-x · Cited by 65
A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma
O’Neil, B. H., Williams-Goff, L. W., Kauh, J. S. W., Bekaii‐Saab, T., Strosberg, J., Lee, R. J., Deal, A., Sullivan, D. M., & Sebti, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15574 · Cited by 30
Self-citationMouse models of K-ras-initiated carcinogenesis
Janssen, K., Abala, M., Marjou, F. E., Louvard, D., & Robine, S. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.004 · Cited by 27
Tzekova, V., Cebotaru, C. L., Ciuleanu, T., Damjanov, D., Ganchev, H., Kanarev, V., Stella, P. J., Sanders, N., Pover, G. M., & Hainsworth, J. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8029 · Cited by 27
Hepatic artery infusion chemotherapy for metastatic colorectal carcinoma
Koea, J., & Kemeny, N. E. (2000) · Seminars in Surgical Oncology · doi:10.1002/1098-2388(200009)19:2<84::aid-ssu2>3.0.co;2-0 · Cited by 16
Cited by
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Metadata
- Authors
- Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., Vasko, V. V., Bloomston, M., Marsh, W., Doyle, L. A., Ellison, G., Grever, M., Ringel, M. D., & Villalona-Calero, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-10
- Volume
- 29
- Issue
- 17
- Pages
- 2357-2363
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157232767
- Cited by
- 303
- References
- 38
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.